References

PRINT AS PDF
  1. Australasian Sexual Health Alliance (ASHA). Australian STI management guidelines for use in primary care [internet]. Last updated December 2018. Available at: http://www.sti.guidelines.org.au/ (last accessed 30 August 2019).

  1. Masciotra S, McDougal JS, Feldman J, Sprinkle P, Wesolowski L, Owen SM. Evaluation of an alternative HIV diagnostic algorithm using specimens from seroconversion panels and persons with established HIV infections. J Clin Virol 2011 52:S17-22.

  1. Gibas KM, van den Berg P, Powell VE, Krakower DS. Drug resistance during HIV pre exposure prophylaxis. Drugs 2019;79:609–19.

  1. Souza MS, Pinyakorn S, Akapirat S, et al. Initiation of antiretroviral therapy during acute HIV-1 infection leads to a high rate of nonreactive HIV serology. Clin Infect Dis 2016;63:555-61.

  1. Laeyendecker O, Redd AD, Nason M, et al. Antibody maturation in women who acquire HIV infection while using antiretroviral preexposure prophylaxis. J Infect Dis 2015;212:754-9.

  1. Donnell D, Ramos E, Celum C, et al; Partners PrEP Study Team. The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion. AIDS 2017;31:2007-16.

  1. Traeger MW, Cornelisse VJ, Asselin J, et al; PrEPX Study Team. Association of HIV preexposure prophylaxis with incidence of sexually transmitted infections among individuals at high risk of HIV infection. JAMA 2019;321:1380-90.

  1. Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM). B positive: all you wanted to know about hepatitis B. A guide for primary care. 3rd ed. 2018. Available at: http://hepatitisb.org.au/ (last accessed 30 August 2019).

  1. Vaccher SJ, Gianacas C, Templeton DJ, et al; PRELUDE Study Team. Baseline preferences for daily, event-driven, or periodic HIV pre-exposure prophylaxis among gay and bisexual men in the PRELUDE Demonstration Project. Front Public Health 2017;5:341.

  1. Grant RM, Lama JR, Anderson PL, et al; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010;363:2587-99.

  1. Danta M, Brown D, Bhagani S, et al; HIV and Acute HCV (HAAC) group. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007;21:983- 91.

  1. Rauch A, Rickenbach M, Weber R, et al; Swiss HIV Cohort Study. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clin Infect Dis 2005;41:395-402.

  1. Hoornenborg E, Achterbergh RCA, Schim van der Loeff MF, et al; Amsterdam PrEP Project team in the HIV Transmission Elimination AMsterdam Initiative, MOSAIC study group. MSM starting preexposure prophylaxis are at risk of hepatitis C virus infection. AIDS 2017;31:1603-10.

  1. Glidden DV, Amico KR, Liu AY, et al. Symptoms, side effects and adherence in the iPrEx open-label extension. Clin Infect Dis 2016;62:1172-7.

  1. Lal L, Audsley J, Murphy D, et al; VicPrEP Study Team. Medication adherence, condom use and sexually transmitted infections in Australian PrEP users. AIDS 2017;31:1709-14.

  1. Grulich AE, Guy R, Amin J, et al; Expanded PrEP Implementation in Communities New South Wales (EPIC-NSW) research group. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study. Lancet HIV 2018;5:e629-37

  1. Spinelli MA, Glidden DV, Rodrigues WC, et al. Low tenofovir level in urine by a novel immunoassay is associated with seroconversion in a preexposure prophylaxis demonstration project. AIDS 2019;33:867-72.